{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:02:30Z","timestamp":1792422150060,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2020,7]]},"abstract":"\n Significance Statement<\/jats:title>\n Although generally effective at raising hemoglobin levels to treat dialysis-dependent CKD anemia, erythropoiesis-stimulating agents such as darbepoetin alfa have safety issues and are less effective in patients with inflammation. In this randomized controlled trial in stable Japanese patients on hemodialysis previously treated with erythropoiesis-stimulating agents, the authors compared roxadustat\u2014an oral hypoxia-inducible factor prolyl hydroxylase inhibitor previously shown to be effective in treating CKD anemia\u2014with darbepoetin alfa. The study found that roxadustat was effective in maintaining hemoglobin within target levels and that its efficacy was noninferior to darbepoetin alfa. Consistent with previous findings, roxadustat showed an acceptable safety profile. These data confirm that oral roxadustat is a valid alternative to injectable erythropoiesis-stimulating agents for dialysis-dependent CKD anemia.<\/jats:p>\n <\/jats:sec>\n \n Background<\/jats:title>\n Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved in China for dialysis-dependent CKD anemia.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This phase 3, 24-week, double-blind, double-dummy study evaluated roxadustat\u2019s noninferiority to darbepoetin alfa for hemodialysis-dependent CKD anemia. We randomly assigned Japanese patients to oral roxadustat three times weekly or to darbepoetin alfa injections once weekly, titrating doses to maintain hemoglobin between 10\u201312 g\/dl. The primary end point was change of average hemoglobin from baseline to weeks 18\u201324 (\n \u2206<\/jats:italic>\n Hb\n 18\u201324<\/jats:sub>\n ). Secondary end points were average hemoglobin and proportion of patients with hemoglobin between 10\u201312 g\/dl (maintenance rate) at weeks 18\u201324, and iron parameters. Safety assessments included treatment-emergent adverse events and adjudicated ophthalmologic findings.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n We randomly assigned 303 patients to roxadustat (\n n<\/jats:italic>\n =151) or darbepoetin alfa (\n n<\/jats:italic>\n =152). The difference between roxadustat and darbepoetin alfa in\n \u2206<\/jats:italic>\n Hb\n 18\u201324<\/jats:sub>\n was \u22120.02 g\/dl (95% confidence interval, \u20130.18 to 0.15), confirming roxadustat\u2019s noninferiority to darbepoetin alfa. Average hemoglobin at weeks 18\u201324 with roxadustat was 10.99 g\/dl (95% confidence interval: 10.88 to 11.10), confirming its efficacy. Among patients with one or more hemoglobin value during weeks 18\u201324, the maintenance rate was 95.2% with roxadustat and 91.3% with darbepoetin alfa. Serum iron, ferritin, and transferrin saturation remained clinically stable with roxadustat; transferrin and total iron binding capacity increased through week 4 before stabilizing. Common treatment-emergent adverse events were nasopharyngitis, shunt stenosis, diarrhea, contusion, and vomiting. The proportion of patients with new or worsening retinal hemorrhage was 32.4% with roxadustat and 36.6% with darbepoetin alfa. We observed no clinically meaningful changes in retinal thickness groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Roxadustat maintained hemoglobin within 10\u201312 g\/dl in patients on hemodialysis and was noninferior to darbepoetin alfa. Treatment-emergent adverse events were consistent with previous reports.<\/jats:p>\n <\/jats:sec>\n \n Clinical Trial registry name and registration number<\/jats:title>\n A Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients with Anemia, NCT02952092 (ClinicalTrials.gov)<\/jats:p>\n <\/jats:sec>","DOI":"10.1681\/asn.2019060623","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:45:14Z","timestamp":1591195514000},"page":"1628-1639","source":"Crossref","is-referenced-by-count":189,"title":["Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan"],"prefix":"10.1681","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct02952092","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02952092","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tadao","family":"Akizawa","sequence":"first","affiliation":[{"name":"Department of Nephrology, Showa University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Iwasaki","sequence":"additional","affiliation":[{"name":"Department of Data Science, Yokohama City University, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Japan-Asia Data Science, Development, Astellas Pharma, Inc., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikatsu","family":"Majikawa","sequence":"additional","affiliation":[{"name":"Japan-Asia Clinical Development 2, Development, Astellas Pharma, Inc., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Reusch","sequence":"additional","affiliation":[{"name":"Development Medical Science Urology and Nephrology, Astellas Pharma Europe B.V., Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"B1-20230829","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"B2-20230829","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"B3-20230829","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1080\/14740338.2016.1182494","article-title":"An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease","volume":"15","author":"Del Vecchio","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"B4-20230829","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/1744-9987.12712","article-title":"Burden of anemia in chronic kidney disease patients in japan: A literature review","volume":"22","author":"Akizawa","year":"2018","journal-title":"Ther Apher Dial"},{"key":"B5-20230829","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness","volume":"12","author":"Johnson","year":"2007","journal-title":"Nephrology (Carlton)"},{"key":"B6-20230829","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with ckd","volume":"69","author":"Gupta","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"B7-20230829","doi-asserted-by":"crossref","first-page":"E389","DOI":"10.3390\/ijms19020389","article-title":"Hypoxia-inducible factor and its role in the management of anemia in chronic kidney disease","volume":"19","author":"Kaplan","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B8-20230829","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients","volume":"45","author":"Locatelli","year":"2017","journal-title":"Am J Nephrol"},{"key":"B9-20230829","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (fg-4592): Correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B10-20230829","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B11-20230829","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (fg-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B12-20230829","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B13-20230829","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1007\/s12325-019-00943-4","article-title":"Roxadustat treatment of chronic kidney disease-associated anemia in japanese patients not on dialysis: A phase 2, randomized, double-blind, placebo-controlled trial","volume":"36","author":"Akizawa","year":"2019","journal-title":"Adv Ther"},{"key":"B14-20230829","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (fg-4592) for the treatment of anemia in patients with ckd","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"B15-20230829","first-page":"5071","article-title":"Effects of HIF-1\u03b1 on diabetic retinopathy angiogenesis and VEGF expression","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"Suppl 1","key":"B16-20230829","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/j.diabres.2007.01.035","article-title":"Novel role of erythropoietin in proliferative diabetic retinopathy","volume":"77","author":"Takagi","year":"2007","journal-title":"Diabetes Res Clin Pract"},{"key":"B17-20230829","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: A randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2019060623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:24:03Z","timestamp":1786130643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.2019060623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2019060623","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]}}}